Chronic Lymphocytic Leukemia
TG Therapeutics has reached an agreement with the FDA regarding a Special Protocol Assessment for a phase III clinical trial exploring ublituximab in combination with ibrutinib for the treatment of patients with chronic lymphocytic leukemia.
Most Popular Right Now
Dr Richard Michaelson and Kimberly Blackwell, MD discuss their decision-making processes when treating patients with metastatic HR+/HER2- breast cancer. View Now